Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665100 · ClinicalTrials.gov registry record · Phase 2
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
A Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT), sponsored by Pulmotect.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 11
- Study locations
NCT06665100: Recruiting Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT), sponsored by Pulmotect.
NCT06665100 is a Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT) that is actively recruiting participants, run by Pulmotect. The registered enrollment target is 100 participants, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06665100, a Phase 2 study of Hematologic Malignancies and Hematopoietic Stem Cell Transplant (HSCT), is actively recruiting participants, sponsored by Pulmotect.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.
Primary Outcome
Determine efficacy of PUL-042 Inhalation Solution on lower respiratory tract complications (LRTC) using the peak post-treatment radiologic severity index (RSI) score in subjects with hematologic malignancies (HM \[lymphoma, multiple myeloma and leukemia\]) and hematopoietic stem cell transplant (HSCT) recipients with documented parainfluenza virus (PIV), human metapneumovirus (hMPV), or respiratory syncytial virus (RSV) infection. The RSI is a quantitative score based on the presence of pulmonar
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PUL-042
Study Locations (11)
California
- City of Hope National Medical Center - Duarte
Georgia
- Northside Hospital - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Minnesota
- University of Minnesota - Minneapolis
New Jersey
- John Theurer Cancer Center - Hackensack
North Carolina
- Lineberger Cancer - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What NCT06665100 shows while recruiting
NCT06665100 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,710-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hematologic Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06665100 lists 11 locations in 11 states (California, Georgia, Maryland).
Frequently Asked Questions
What is clinical trial NCT06665100 about?
NCT06665100 is a clinical study titled "PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)". The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral ...
What is the current status of trial NCT06665100?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-27. Estimated completion is 2026-05.
What conditions does trial NCT06665100 study?
This clinical trial studies the following conditions: Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT).
What interventions are being tested in trial NCT06665100?
The interventions under investigation include: Placebo (DRUG), PUL-042 (DRUG).
Who is sponsoring clinical trial NCT06665100?
This trial is sponsored by Pulmotect, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665100 being conducted?
This trial has 11 study locations across California, Georgia, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06665100's enrollment target sits among peer trials
100 17th of 45 higher than 29 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
RECRUITING · Phase 2
-
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI